secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001104659-23-026402
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports Q4 net income $4.5M vs loss; ARCALYST revenue $122.5M in FY2022
-------------------------------------------------------------------------------

- ARCALYST net product revenue $39.9M in Q4, $122.5M full-year 2022; FY2023 guidance $190-205M.
- Total revenue $61.9M Q4, $220.2M full-year; license revenue from Roche/Genentech and Huadong.
- Net income $4.5M Q4 vs loss $36.3M; full-year net income $183.4M includes $172.3M tax benefit.
- Cash $190.6M, no debt; expects cash to fund operations into at least 2025.
- KPL-404 Phase 2 RA trial advancing; efficacy data expected first half 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/0001104659-23-026402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923026402/tm237813d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer